Feb 6 (Reuters) - Celgene Corp:
* CELGENE CORPORATION ANNOUNCES POSITIVE RESULTS FROM THE PIVOTAL PHASE III ‘OPTIMISMM’ STUDY OF POMALYST/IMNOVID® FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA
* CELGENE CORP - STUDY MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage: